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Some individuals are at risk of anti-D alloimmunization if they 
inherit D antigens that are qualitatively and/or quantitatively 
different than wild-type D. We hypothesized that patients 
who showed serologically inconsistent, weak, or historically 
discordant D typing results by microplate direct agglutination 
(MDA) on NEO or Echo (Immucor, Norcross, GA) might be at 
risk of carrying RHD allelic variants. The present study was 
designed to evaluate patients with RHD allelic variants if they 
presented with weakly reactive D typing results on the NEO 
or Echo. Patients were selected for RHD genotyping if their 
specimens showed weak reactivity with either series 4 or series 
5 anti-D typing reagent, if the strength of reactivity was ≤1+ 
on the NEO or Echo, or if historical or current D typing results 
were discordant with current results. Patients selected for RHD 
genotyping were also tested by saline tube testing using the same 
anti-D series 4 and 5 reagents. Genotyping was performed by the 
Immucor genotyping laboratory in Warren, NJ. Of 80 patients 
whose samples met study inclusion, 52 (65.0%) were found to 
have RHD allelic variants. Sixteen patients (20.0%) expressed 
possible Ceppellini effect reactivity. Most importantly, 51.25 
percent of the patients who presented with weakly reactive D 
typing results by MDA testing on the NEO (≤1+) or Echo (≤1+) had 
RHD allelic variants that were associated with the potential for 
anti-D alloimmunization. Laboratories that use MDA testing on 
the Neo or Echo for D typing should consider that female patients 
of childbearing age might be at risk of anti-D alloimmunization 
if they are classified as D+ based on weakly reactive D typing 
results. Immunohematology 2021;37:165–170. DOI: 
10.21307/immunohematology-2021-027. 
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Anti-D alloimmunization is reported to occur in up to 80 
percent of D– recipients who are transfused with D+ blood.1 
Some individuals who inherit D antigens that are qualitatively 
different from that of wild-type D also can develop anti-D 
after exposure to D+ blood; such individuals express so-called 
partial D. Other patients can inherit variant(s) that lead to a 
quantitative reduction in the level of cell surface expression 
of D, referred to as weak D; these individuals typically do not 
form anti-D. In general, we refer to both groups of patients 
as having RHD allelic variants. Individuals who have RHD 
allelic variants that encode partial D phenotypes may develop 
anti-D after transfusion or pregnancy. Identifying which 
patients who express RHD allelic variants are at risk for 
anti-D alloimmunization helps to mitigate risks of hemolytic 
transfusion reactions or hemolytic disease of the fetus and 
newborn. Historically, the standard serologic approach to 
identifying such patients was to perform a test for weak 
D; if positive, the patient would be classified as weak D. 
Alternatively, some of these weaker reactions could be due to 
the Ceppellini effect, which is characterized by a reduction of 
D antigen density when a haplotype that is C+ is inherited in 
trans to a D+ haplotype: for example, r′ (Ce) is in trans to R0 
(Dce)  (R0r′). As molecular assays have become more widely 
available, it is now possible to determine the molecular basis 
for a patient’s D variant expression and the patient’s risk of 
producing anti-D.
The frequency of patients who express RHD allelic variants 
can be contingent upon the patient population observed. Red 
blood cell (RBC) phenotypes with a weak expression of D 
occur in 0.2–1 percent of individuals of European ancestry.2 A 
study of central European populations showed that more than 
90 percent of weak D individuals fall into the weak D type 1, 
2, or 3 categories.3 A Canadian Blood Services study reported 
0.4 percent of prenatal women expressed weak D when testing 
a predominantly white population. Two-thirds of the weak D 
individuals in that study were in the weak D type 1, 2, or 3 
categories.4 Two other studies showed the prevalence of RHD 
allelic variants in multiethnic populations to range from 0.2 
to 2.2 percent, with a greater diversity of variants associated 
with anti-D alloimmunization.5,6 Our institution serves 
diverse multiethnic populations with a high proportion of 
patients of Central American and Hispanic heritage. Inpatient 
demographics for the Los Angeles County + University of 
Southern California (LAC+USC) Medical Center indicate that 
62 percent of patients admitted to the hospital identify as 
Hispanic originating from Central America, South America, 
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or a Caribbean island; 11 percent as African ancestry; 5 
percent as Asian ancestry; 4 percent as European ancestry; 
and 2 percent as multiethnic. The remaining 16 percent were 
of unknown ethnic ancestry.
Clarke et al.4 suggested a manual testing algorithm using 
anti-D reagent to predict the necessity of RHD genotyping. We 
wondered if weakly reactive D typing results by an automated 
microplate direct agglutination (MDA) testing platform might 
also predict the necessity of RHD genotyping and be associated 
with patients who carry RHD alleles encoding RHD allelic 
variants. Such typing results might identify individuals who 
appear to be D+ but are at risk of anti-D alloimmunization, 
such as women of child-bearing potential (WOCBP). Many 
practitioners believe that WOCBP who express an RHD allelic 
variant should be transfused with D– RBCs and, if pregnant, 
should be given Rh immune globulin (RhIG). To assess if 
an automated direct agglutination platform could be used to 
detect D+ patients at risk of forming anti-D, we evaluated the 
likelihood that decreased reactivity (either indeterminate [?] or 
1+) of D typing by MDA on automated analyzers (Galileo Echo 
[Echo] or Galileo NEO [NEO]; Immucor, Norcross, GA) can 
reliably predict the necessity of RHD genotyping in WOCBP 
without additional tube testing.
Materials and Methods
Sample Inclusion Criteria
All testing was performed using a microplate hemag-
glutination method on an automated NEO or Echo. All type 
and screen samples submitted to the transfusion service for 
ABO/D typing that produced weak D typing on either the 
NEO or Echo were included in the study. Whole blood samples 
were collected from June 2015 until September 2016.
Inclusion criteria for further workup was then determined 
for both the NEO and the Echo. For the NEO, any sample that 
did not type 0/0 (D–) or 3+/3+ (D+) or greater using either or 
both series 4 and series 5 anti-D reagent was included in the 
study. (The NEO reports results of 0, ?, 1, 3, and 4+. It does not 
report 2+ for testing performed on the platform.) For the Echo, 
any sample that did not type 0/0 (D–) or 2+/2+ or greater (D+) 
using either or both series 4 and series 5 anti-D reagent was 
included. (The Echo reports 0, ?, 1, 2, 3, and 4+.) In addition, 
any sample with a typing result as indeterminate (?) or 1+ with 
either or both anti-D series reagent by either platform was 
included. All identified samples were then tested by saline tube 
method using series 4 and series 5 anti-D reagent. The saline 
tube testing demonstrated variable results ranging from 0 to 
4+. Patients with historically discrepant or discrepant types 
during the same admission in the absence of transfusion were 
also evaluated.
Transfusion Service Testing and Interpretation
Any sample meeting the inclusion criteria that was tested 
in the previously described algorithm needed a new sample 
for molecular testing and interpretive guidance for the staff in 
the blood bank. To meet this need, a request was submitted 
to the patient care area to collect a new sample for molecular 
RHD genotype determination. In the interim, patients who 
had indeterminate or discrepant test results were designated 
as D– and, if needed, D– RBC products and/or RhIG were 
issued.
RH Genotyping
Genotyping was performed by the Immucor genotyping 
laboratory (Warren, NJ). DNA was extracted using the 
automated QIAcube (QIAGEN, Hilden, Germany) and was then 
quantified on the Nanodrop (ThermoScientific, Waltham, MA). 
The samples were tested by an escalating algorithm of molecular 
assays. First, samples were tested using RHD BeadChip 
(Immucor). This commercially available assay can identify 78 
polymorphisms for weak and variant D alleles. If the sample had 
no identifiable allelic variants on the RHD BeadChip, the sample 
was tested using RHDxp prototype assay. This prototype assay 
uses the proprietary elongation-mediated multiplexed analysis 
of polymorphisms to identify the presence or absence of 11 
additional variants/alleles, including the following that are not 
included in the RHD BeadChip: RHD DVII (RHD*DVII.1), 
RHD DAU-0 (RHD*DAU0), weak D type 73 (RHD*weak D 
type 73), RHD*(1-9)-CE (10) (RHD*01N.02), RHD-CE (2-9)-
D (RHD*01N.03), RHD-CE (8-9)-D (no designation assigned), 
RHD-CE (2-7)-D2 (RHD*01N.05), RHD-CE (2-9)-D2 (no 
designation assigned), RHD-CE (1-9)-D (RHD*01N.02), RHCE 
(1-9)-D (10) (no designation assigned), and RHD (del Ex9) (no 
designation assigned).7 If samples showed no allelic variants 
by RHDxp, they were evaluated for RHD zygosity.8 Lastly, if 
zygosity identified the patient as at least hemizygous for RHD, 
RHCE BeadChip (Research Use Only) was performed to identify 
gene interactions as a possible cause for a weak D presentation 
(possible Ceppellini effect) (Fig. 1).
Results
From June 2015 through September 2016, there were 
41,170 type and screen samples sent to LAC+USC Medical 
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Center and other Los Angeles County–affiliated hospitals. 
Overall, 80 samples (0.2%) met criteria for molecular testing.
RHD allelic variants were identified in 52 of the 80 samples 
(65%), and the Ceppellini effect was identified as a possible 
cause for weak D reactivity in 16 of the 80 samples (20%) 
(Table 1). Therefore, of the 80 samples tested, 52 (65%) were 
resolved by this genotyping algorithm. Although people of 
African ancestry composed only 11 percent of the admissions 
seen, they represented 25 of 52 (48.1%) of the identified 
patients who express RHD allelic variants. More significant is 
the finding that of the 52 samples resulting from mutations 
that encode weak D or a partial D antigen expression, 41 
of 80 (51.25%) expressed RHD allelic variants, with the 
potential for the patient to be at risk for alloimmunization if 
the patient was exposed to D+ RBCs via transfusion(s) and/or 
pregnancy(ies) (Table 1). RHD zygosity and RHCE BeadChip 
testing identified 16 samples that may possibly represent the 
Ceppellini effect. All 16 samples were hemizygous for the 
RHD gene with at least one RHCE gene expressing C (Tables 
2 and 3). Description of determination of RHD zygosity can 
be found in Ishtiaq et al.,8 where they state “primers specific 
to the hybrid rhesus box and for an intact downstream rhesus 
box were designed and used in multiplex PCR to generate 
marker amplicon for RHD deletion or presence, respectively.” 
Twelve samples were negative when tested by RHD BeadChip, 
RHDxp; expressed no RHCE*C allele from RHCE BeadChip; 
and were homozygous for the RHD allele by RHD zygosity. We 
ultimately labeled these samples as possible wild-type RHD, 
representing 15 percent of the samples tested.
At the completion of the molecular testing performed on 
the samples, the results from the tube testing and those from 
the automated instruments were reviewed and compared. 
Several samples that were shown to express RHD allelic 
variants typed ≥2+ by tube testing. Had genotyping not 
been done, their samples would have been considered D+ 
serologically.
Discussion
The present study demonstrates that some patients who 
carry RHD alleles encoding RHD variants can be identified 
when molecular testing is done following weak D typing (≤1+) 
results by MDA. This finding is important because over half 
of the individuals identified as expressing RHD allelic variants 
in this study are at risk of anti-D alloimmunization. Our data 
build on other reports by Denomme et al.9 and Clarke et al.4
Clarke et al.4 also evaluated D typing on the Galileo NEO 
automated platform in conjunction with tube testing. In 
their study, they examined prenatal maternal samples and 
identified 351 individuals who underwent RHD genotyping. 
They used two anti-D reagents on the automated platform 
and an additional anti-D reagent for manual tube testing. 
If, on the automated platform, the result was ≥1+ for both D 
antisera, the patient was classified as D+. If the patient had 
discrepant results for the D4 and D5 reagents (e.g., 1+/?, 
0/1+, or 1+/3+), direct agglutination by tube was performed 
with D4, D5, and Novoclone (Immucor) reagents. If all anti-D 
reagents tested negative, the patient was called D–; if two or all 
three anti-D reagents tested ≥2+, the patient was called D+; if 
RHD BeadChip variant detected? RHDxp variant detected?
YES YES YES
NO NO NOPossible Ceppellini effect? 










Fig. 1 The molecular workflow shown begins with the standard RHD BeadChip analysis. If no mutations were detected by that method, the 
experimental RHDxp molecular assay was used to assess for 11 additional variants. Individuals with negative results from both assays were 
assessed for RHD zygosity and the presence of RHCE*C alleles to evaluate for possible Ceppellini effect. If all assays were not associated 
with a possible molecular cause for the weak reactivity seen serologically, they were classified as possible wild-type D.
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serologic differences were ≥2 grades in reaction strength (e.g., 
one reagent ≤1+ and one or two reagents ≥3+) with different 
reagents, or was discrepant with historical D typing, then 
genotyping was performed.4 Following this approach, the 
majority of patients in the Clarke et al.4 study (213 of 315) were 
shown to express RHD allelic variants.
Our study ran samples on both the NEO and Echo 
platforms to evaluate concordance of serologic results. In 
total, 87.5 percent of the samples tested on both the NEO and 
Echo showed the same weak reactivity or discordant D typing 
that would initiate molecular evaluation. From this finding, 
we developed an alternative to the algorithm proposed by 
Clark et al.4 This workflow would allow for a similar level of 
Table 1. RHD allelic variants identified in samples submitted for molecular testing
D phenotype Encoding variant allele(s)†
Number of  
samples
Anti-D D4/D5  
on NEO/Echo
Anti-D D4/D5  
in tube Ethnicity
Weak D type 4.0 or 4.3 RHD*DAR3.01 or RHD*DAR5 20 0–3+/0–1+ 1–4+/0–4+ HS-5
EA-2
AA-13
DAR RHD*DAR 10 0–?/0–? 0–3+/0–2+ AA-4
HS-6
DAR RHD*DAR/RHDψ 2 0–?/0 1+/1+ AA-1
NR-1
DCS1 or DFV RHD*DCS1 or  
RHD*DFV/RHD*DIIIa-CE(4-7)-D‡
1 1–3+/? 1+/1+ AA
Weak D type 4.0 or 4.3 RHD*DAR3.01 or  
RHD*DAR5/RHD*DIIIa-CE(4-7)-D‡
1 ?/0 0/0 AA
DOL1 or DOL2 RHD*DOL1 or 
RHD*DOL2/RHD*DIIIa-CE(4-7)-D‡
1 1–4+/0–? 2+/2+ AA
DAU2 RHD*DAU2 2 0–?/?–1+ 2–4+/1–2+ HS-1
NR-1
DVII RHD*DVII.1 1 1–4+/0–? 1+/2+ EA
RHDψ/DAU4 or DV type 5 RHD*DAU4 or RHD*DV.5 1 0–?/2–4+ 2+/4+ AA
RHDψ/Weak D type 4.0 or 4.3 RHD*DAR3 or RHD*DAR4 1 0–1+/0–? 2+/2+ AA
DV type 2 RHD*DV.2 or 
DBS1 RHD*DBS1 or 
DV type 7 RHD*DV.7
1 0–?/0 1+/0 EA
Weak D type 1 RHD*weak D type 1§ 2 0–3+/0–3+ 1+/1+ EA-1
AA-1
Weak D type 2 RHD*weak D type 2§ 1 0/0 1+/1+ HS(NR)
DVII/Weak D type 2 RHD*DVII.1/RHD*weak D type 2§ 1 4+/1–3+ 4+/3+ EA




Exon 8 hybrid/deletion  RHD*DEL30 1 2+/1+ 4+/3+ HS
†If only one allele is reported, the patient is either homozygous (inheriting two copies of a gene or DNA sequence in diploid cells) or hemizygous (inheriting only 
one copy of a gene or DNA sequence in diploid cells). Limitations of the testing platform at times could not distinguish between two or more variants. Therefore, 
entries may indicate two possible variants for the inherited allele for the same phenotype.
‡RHD*DIIIa-CE(4-7)-D: Hybrid allele that expresses a partial C. It does not express D.
§No risk of anti-D alloimmunization.
D4/D5 = series 4 and series 5 anti-D reagent; Ψ = pseudogene (D– phenotype); ? = equivocal/indeterminate; AA = African ancestry; HS = Hispanic 
ancestry; EA = European ancestry; OT = other; NR = not reported.
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sensitivity to detect patients with expression of RHD allelic 
variants and would be effective and efficient for community 
and university hospitals using the Echo platform. We 
determined that the need to do any additional D typing was 
unnecessary when including all patients who react as ≤1+ with 
either or both the D4 and D5 antisera by MDA. We captured “at 
risk” patients who were omitted by the Clarke et al.4 algorithm.
Our data, though limited, suggest some salient points. 
We found that individuals who were reported to show 
positive D typing results of ≤1+ by the Echo or the NEO were 
likely to have a molecular cause for the decreased D typing 
strength (85.0%). Most of the samples that tested ≤1+ were 
shown to have a specific RHD allelic variant(s) that could 
result in qualitative or quantitative changes in D (65%). 
Most importantly, approximately 51.25 percent of the RHD 
allelic variants identified were related to partial D that have 
been previously reported to be associated with risk of anti-D 
alloimmunization. Our data suggest that transfusion services 
using the NEO or Echo microplate hemagglutination platforms 
with series 4 and series 5 anti-D reagent should consider any 
patient with a weakly (≤1+) reactive D typing result as D– until 
proven otherwise by RH genotyping. This finding is important 
because the Galileo NEO and Echo operator manual suggests 
that 1+ D results will trigger the instrument to report the 
sample as D+. Thus, laboratories using only the automated 
MDA testing platforms may be classifying some patients who 
test 1+ with both series 4 and series 5 anti-D reagent as D+, 
yet some of these patients are at risk for developing anti-D if 
transfused with D+ blood.10,11 Accordingly, any WOCBP with 
D typing reactivity of ≤1+ by NEO or Echo using either series 
antisera should be evaluated with our algorithm (Fig. 2) and 
managed as D– until RHD genotyping results are known. Our 
study suggests that if Clarke et al.4 had performed genotyping 
for patients typed as 1+ for both the D4 and D5 antisera, they 
might have identified additional RHD allelic variants.
Identification of these variants at community hospitals 
often raises concerns over increased use of D– RBCs. 
Retrospective evaluation indicates that the number of D– 
Atypical D typing results on NEO/Echo platforms
Fig. 2 The algorithm proposed is one that eliminates the need for manual testing in the lab. Samples with results ≤1+ with one or both D4/D5 
antisera in women of child-bearing age and other high-risk populations are immediately referred for molecular testing. If the variant detected 
indicates weak D type 1, 2, or 3, the woman will be treated as D+. If the variant detected indicates a weak D allele other than type 1, 2, or 3 or 
a partial D allele, the woman should be treated as D–. If the patient has no variant identified by commercially available RHD molecular assays, 
RHD exon sequencing should be performed to assess for novel mutations that are potentially clinically significant.
≤1+ on Neo/ECHO with either or both D4 & D5 
or 
discordant D type with historical sample or 
discordant D type on two current samples
Weak D 
1, 2, & 3
Alleles other than weak D 1,2,3 
or 
partial D




Treat as D+ Treat as D– RHD exon sequencing
Table 3. RHCE genotyping results supporting the classification of 
possible Ceppellini effect
RHCE BeadChip  
result
RHD zygosity  
result
Presumed Rh  
haplotype Interpretation




Ccee Hemizygous R0r′ (Dce/Ce)
Ccee Hemizygous R0r′ (Dce/Ce)
CCeeCW Hemizygous R1r′ (DCe/Ce)
Ccee Hemizygous R0r′ (Dce/Ce)
Ccee Hemizygous R0r′ (Dce/Ce)
CCee Hemizygous R1r′ (DCe/Ce)
CcEE Hemizygous R2ry (DcE/Ce) 
CCee Hemizygous R1r′ (DCe/Ce)
CCee Hemizygous R1r′ (DCe/Ce)
CCee Hemizygous R1r′ (DCe/Ce)
CCee Hemizygous R1r′ (DCe/Ce)
Ccee Hemizygous R0r′ (Dce/Ce)
CcEe Hemizygous R0ry (Dce/CE)
Ccee Hemizygous R0r′ (Dce/Ce)
Ccee Hemizygous R0r′ (Dce/Ce)
† Hemizygous = only one copy of a gene or DNA sequence is present in 
diploid cells.
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transfusions have remained flat (2015 [15,227] until 2019 
[14,399]) since protocol implementation. In addition, there 
was a low prevalence of affected D typing, representing 0.1 
percent of samples after going through the algorithm. Because 
this policy is directed primarily to ensure WOCBP will not 
be adversely affected by weak typing of D, our data indicate 
that the implementation of this protocol has not dramatically 
increased D– RBC use at our institution.
There are some pertinent limitations to this study. We 
acknowledge that there is a limited sample size in this study, 
which may accentuate an unintended bias toward abnormal 
results. Our data set includes only patients whose sample 
resulted as ≤1+ for one or both series 4 or series 5 anti-D reagent. 
We were not able to keep in line with the recommendations from 
Sandler et al.12 of testing samples that were ≤2+ when testing 
samples on both the NEO and the Echo. We did not identify 
any patients whose sample resulted as 2+ for both the D4 and 
D5 series when doing D typing on the Echo. Therefore, we 
cannot comment whether patients with 2+ D typing results by 
MDA are at increased risk of expressing an RHD allelic variant.
In addition to the limitations, we identified a significant 
benefit to our algorithm. This benefit relates to the performance 
of D typing by MDA compared with manual tube typing. 
Although the MDA platform for D typing is similar to low-
ionic-strength saline–based tube D typing, the sensitivity of 
MDA methods to detect RHD allelic variants may be enhanced 
by the manner in which the cell button shakes off during MDA 
versus that by the technologist during manual tube typing. 
There is uniformity of performance on the instrument (in that 
it shakes the button a set number of times) compared with 
inter-operator variability in manual tube testing, because the 
technologist generally stops shaking the tube and grades the 
reaction strength once the button is dislodged. The samples 
that were labeled as presumed “wild-type” D or Ceppellini 
effect were classified as such because full exon sequencing was 
not performed.
Conclusion
Laboratories using the automated MDA platform may be 
classifying some patients as D+ who are at risk for developing 
anti-D. The data presented here suggest that WOCBP who 
have RBCs that react positively but ≤1+ by an automated MDA 
platform should be managed as if they were D– until RHD 
genotyping or sequencing can be performed to determine 
whether they express a partial D phenotype that puts them at 
risk of forming anti-D.
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